NATCO Pharma Limited (BOM:524816)
India · Delayed Price · Currency is INR 884.95
+0.65 (0.07%)
At close: Sep 19, 2025
NATCO Pharma Revenue
NATCO Pharma had revenue of 13.29B INR in the quarter ending June 30, 2025, a decrease of -2.47%. This brings the company's revenue in the last twelve months to 43.96B, up 1.08% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.32B with 10.74% growth.
Revenue (ttm)
43.96B
Revenue Growth
+1.08%
P/S Ratio
3.60
Revenue / Employee
10.47M
Employees
4,199
Market Cap
158.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Bajaj Finance | 387.76B |
NATCO Pharma News
- 1 day ago - Natco Pharma receives US FDA’s VAI classification for Hyderabad unit - Business Upturn
- 9 days ago - Natco Pharma moves closer to Adcock Ingram acquisition with shareholder vote set for October - Business Upturn
- 4 weeks ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 4 weeks ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 5 weeks ago - Brokerage recommendations for August 14: Muthoot Finance, Va Tech Wabag, JSPL, VMM, BPCL, Devyani, Apollo Hospitals, HDFC Life, Infosys, Brainbees, United Spirits, Motherson, Jubilant Food, PI Industries, Natco Pharma, ONGC in focus - Business Upturn
- 5 weeks ago - Natco Pharma board declares interim dividend of Rs 2 per share for FY26 - Business Upturn
- 5 weeks ago - NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY - Business Upturn
- 2 months ago - Natco Pharma gets EIR from USFDA for Hyderabad API facility - Business Upturn